| Assessment Status | Rapid Review Complete |
| HTA ID | 25022 |
| Drug | Infliximab |
| Brand | Remsima® |
| Indication | Infliximab (Remsima®) is indicated for the treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. It is also indicated for treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). |
| Assessment Process | |
| Rapid review commissioned | 18/03/2025 |
| Rapid review completed | 11/04/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that infliximab (Remsima®), for Crohn’s disease dose escalation, not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
